x
Norris Cotton Cancer CenterNorris Cotton Cancer Center
In This Section

Comprehensive Breast Program Clinical Trials

A clinical trial is one of the final steps in a long and careful cancer research process that is looking for better ways to prevent, diagnose, or treat cancer. Clinical trials test new medical approaches in patients with cancer, and are important to developing new treatments for cancer. Many of the "standard treatments" that patients with cancer receive today were developed based on the results of previous clinical trials.

The following is a list of clinical trials with which this cancer care program is currently involved. Talk to your doctor to find out if a clinical trial is right for you.

Breast-Female Clinical Trials
A Phase I Dose Escalation Study of POL6326 with Eribulin in Patients with Relapsed Metastatic Breast Cancer
Breast-Female
F14043
Kaufman
A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) (KEYNOTE-086)
Breast-Female
F15108
Kaufman
A Phase III Trial Of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost For Early-Stage Breast Cancer
Breast-Female
R1005
Hartford
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Breast-Female
S1007
Chamberlin
A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Breast-Female
NRG-BR002
Jarvis
A Phase Ib/II, Multicenter, Study of the Combination of LEE011 and BYL719 with Letrozole in Adult Patients with Advanced ER+ Breast Cancer
Breast-Female
F16015
Kaufman
A Proof of Principle, Open Label Clinical Trial: Evaluating Breast Cancer Response to Neoadjuvant Chemotherapy in vivo Using NIR Imaging
Breast-Female
D16075
Jiang
A Prospective Study of Partial Breast Adjuvant Radiation Therapy After Resection of Borderline and Malignant Phyllodes Tumors
Breast-Female
D0929
Barth Jr.
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Breast-Female
NSABP-B55
Arrick
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCl in Postmenopausal Women with Metastatic Estrogen Receptor Positive, Her2 Negative Breast Cancer
Breast-Female
A011203
Kaufman
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Breast-Female
R1304
Hartford
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Breast-Female
EA1131
Chamberlin
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3, N1) Who Have Positive Sentinel Lymph Node Disease After Receiving Neoadjuvant Chemotherapy.
Breast-Female
A011202
Rosenkranz
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
Breast-Female
E2112
Kaufman
A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab plus Pertuzumab plus a Taxane Following Anthracyclines versus Trastuzumab Emtansine plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer
Breast-Female
F14005
Kaufman
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer Who Desire Pregnancy
Breast-Female
A221405
Schwartz
A Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients with Palpable Cancers
Breast-Female
D15120
Barth Jr.
A Study to Evaluate the use of Supine MRI Images in Breast Conserving Surgery
Breast-Female
D0928
Barth Jr.
ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
Breast-Female
A011106
Kaufman
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer
Breast-Female
F12189
Kaufman
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Breast-Female
F15122
Kaufman
Cyclophosphamide and Doxorubicin (CA x 4 Cycles) Versus Paclitaxel (4 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0--3 Positive Axillary Lymph Nodes: A Phase III Randomized Study
Breast-Female
C40101
Kaufman
IBCSG-24-02: A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT)
Breast-Female
C-SOFT
Kaufman
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
Breast-Female
Z11102
Rosenkranz
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting
Breast-Female
SF16126
Paulsen
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Breast-Female
H16006
Kaufman
POLLY: Phase II Pre-emptive OsciLLation of ER activitY levels through alternation of estradiol/anti-estrogen therapies prior to disease progression in ER+/HER2- advanced breast cancer
Breast-Female
D14122
Kaufman
Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer
Breast-Female
S0221
Schwartz
Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel with or without Trastuzumab as Adjuvant Treatment for Women with HER-2 Overexpressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer
Breast-Female
C49909
Kaufman
Presurgical treatment with letrozole in patients with early-stage breast cancer
Breast-Female
D13236
Schwartz
Reducing Disparities in Health for Vulnerable Populations in NH and VT: Journey Forward Cancer Survivor Care Planning in the Rural Northeast
Breast-Female
FED11061
Pace
Breast-Male Clinical Trials
A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) (KEYNOTE-086)
Breast-Male
F15108
Kaufman
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Breast-Male
NSABP-B55
Arrick
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Breast-Male
EA1131
Chamberlin
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
Breast-Male
E2112
Kaufman
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer
Breast-Male
F12189
Kaufman
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
Breast-Male
Z11102
Rosenkranz
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Breast-Male
H16006
Kaufman
Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer
Breast-Male
S0221
Schwartz
Reducing Disparities in Health for Vulnerable Populations in NH and VT: Journey Forward Cancer Survivor Care Planning in the Rural Northeast
Breast-Male
FED11061
Pace

0